Evolus, Inc. (EOLS) Financial Statements (2024 and earlier)

Company Profile

Business Address 520 NEWPORT CENTER DRIVE
NEWPORT BEACH, CA 92660
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments41,70531,46353,92265,57284,484106,671
Cash and cash equivalents41,70531,46353,92265,57284,484106,671
Receivables28,99623,45522,44820,92021,02616,800
Inventory, net of allowances, customer advances and progress billings19,85923,41818,85221,56512,2893,615
Inventory19,85923,41818,85221,56512,2893,615
Prepaid expense4,2974,1593,9023,6564,7244,533
Other current assets1,6031,5901,6784,23311,42411,309
Total current assets:96,46084,085100,802115,946133,947142,928
Noncurrent Assets
Operating lease, right-of-use asset1,5231,7381,9472,1492,3462,537
Property, plant and equipment2,3532,5952,6161,8821,4551,303
Intangible assets, net (including goodwill)68,42469,13569,80570,31670,62371,240
Goodwill21,20821,20821,20821,20821,20821,208
Intangible assets, net (excluding goodwill)47,21647,92748,59749,10849,41550,032
Other noncurrent assets2232,6822,8132,4262,5482,654
Total noncurrent assets:72,52376,15077,18176,77376,97277,734
TOTAL ASSETS:168,983160,235177,983192,719210,919220,662
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:24,18422,10924,79429,88328,53721,139
Employee-related liabilities7,0945,6203,710
Accounts payable7,83510,1858,935   
Accrued liabilities24,18422,10924,794   
Other undisclosed accounts payable and accrued liabilities(7,835)(10,185)(8,935)22,78922,91717,429
Estimated litigation liability   5,0005,0005,0005,000
Other undisclosed current liabilities17,16518,56916,71516,38817,99414,561
Total current liabilities:41,34940,67846,50951,27151,53140,700
Noncurrent Liabilities
Long-term debt and lease obligation94,82972,04671,87973,20373,29873,391
Long-term debt, excluding current maturities94,82972,04671,87971,71271,54571,381
Liabilities, other than long-term debt6689621,246252923
Deferred income tax liabilities222222252923
Operating lease, liability6469401,2241,4911,7532,010
Other undisclosed noncurrent liabilities39,10039,60039,85039,00039,20039,300
Total noncurrent liabilities:134,597112,608112,975112,228112,527112,714
Total liabilities:175,946153,286159,484163,499164,058153,414
Equity
Equity, attributable to parent(6,963)6,94918,49929,22046,86167,248
Common stock111111
Additional paid in capital523,729519,449516,129513,717510,879507,733
Accumulated other comprehensive loss(468)(416)(337)(368)(165)(103)
Accumulated deficit(530,225)(512,085)(497,294)(484,130)(463,854)(440,383)
Total equity:(6,963)6,94918,49929,22046,86167,248
TOTAL LIABILITIES AND EQUITY:168,983160,235177,983192,719210,919220,662

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues49,34641,72143,64633,89937,16333,908
Cost of revenue(21,016)(13,768)(15,075)(15,411)(17,588)(14,138)
Cost of goods and services sold(14,712)(12,146)(13,370)(13,490)(15,819)(13,208)
Gross profit:28,33027,95328,57118,48819,57519,770
Operating expenses(43,448)(39,993)(39,208)(36,385)(40,923)(35,218)
Operating loss:(15,118)(12,040)(10,637)(17,897)(21,348)(15,448)
Nonoperating income (expense)18361161(24)(20)(7)
Investment income, nonoperating1649977384 
Other nonoperating income (expense)19(38)84(62)(24)(7)
Interest and debt expense(3,182)(2,789)(2,631)(2,343)(2,075)(2,048)
Loss from continuing operations before income taxes:(18,117)(14,768)(13,107)(20,264)(23,443)(17,503)
Income tax expense (benefit)(23)(23)(57)(12)(28)2
Loss from continuing operations:(18,140)(14,791)(13,164)(20,276)(23,471)(17,501)
Loss before gain (loss) on sale of properties:(20,276)(23,471)(17,501)
Net loss attributable to parent:(18,140)(14,791)(13,164)(20,276)(23,471)(17,501)
Other undisclosed net income available to common stockholders, basic      103
Net loss available to common stockholders, diluted:(18,140)(14,791)(13,164)(20,276)(23,471)(17,398)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(18,140)(14,791)(13,164)(20,276)(23,471)(17,501)
Comprehensive loss:(18,140)(14,791)(13,164)(20,276)(23,471)(17,501)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(52)(79)31(203)(62)103
Comprehensive loss, net of tax, attributable to parent:(18,192)(14,870)(13,133)(20,479)(23,533)(17,398)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: